Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.
Bone abnormalities affect all individuals with Down syndrome (DS) and are linked to abnormal expression of DYRK1A, a gene found in three copies in people with DS and Ts65Dn DS model mice. Previous work in Ts65Dn male mice demonstrated that both genetic normalization of Dyrk1a and treatment with ~9 m...
Main Authors: | Raza Jamal, Jonathan LaCombe, Roshni Patel, Matthew Blackwell, Jared R Thomas, Kourtney Sloan, Joseph M Wallace, Randall J Roper |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0264254 |
Similar Items
-
Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models
by: Raza Jamal, et al.
Published: (2022-01-01) -
Characterization of the Synergistic Antioxidant Activity of Epigallocatechin Gallate (EGCG) and Kaempferol
by: Qiang Zhang, et al.
Published: (2023-07-01) -
Mechanism of (−)-epigallocatechin gallate (EGCG) dimerization by low-temperature plasma
by: Seungil Park, et al.
Published: (2022-09-01) -
Antioxidant and antiviral activities of lipophilic epigallocatechin gallate (EGCG) derivatives
by: Ying Zhong, et al.
Published: (2012-01-01) -
Screening of epigallocatechin-3-gallate (EGCG) content in camellia sinensis products
by: Amran, Syazwani Itri, et al.
Published: (2018)